Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nvidia Corp (NVDA) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Nvidia CorpTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Nvidia Corp vs Zimmer Biomet Holdings Inc — how do they compare? Nvidia Corp trades at $220.4 (market cap $5.27T), while Zimmer Biomet Holdings Inc trades at $97 (market cap $18.55B). The key difference: Nvidia Corp is far larger — about 284.1× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (0.99%). Which is the better fit depends on your goals.

NVDAZBH
Market Cap
$5.27T$18.55B
Sector
TechnologyHealth
52-Week High
$235.75$107.71
52-Week Low
$165.17$79.58
Enterprise Value
$5.20T$25.61B
Dividend Yield
0.46%0.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nvidia Corp

NVIDIA (NVDA) trades at $217.56, down 2.86% over the past 24 hours, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.87 exceeding the $1.76 estimate. Revenue surged to $130.50B in 2025, driving a net income margin of 62.97% and robust cash flow from operations of $64.09B. Analyst sentiment remains overwhelmingly positive, with a consensus price target of $325.86.

The outlook for NVDA is favorable, supported by accelerating AI chip demand and a dominant market position. Key opportunities include sustained revenue growth and expanding profitability, while risks involve heightened competition, potential peak AI spending, and market volatility. The stock's current valuation metrics, such as a P/E of 33.31, reflect high growth expectations that must be met to justify further upside.

Zimmer Biomet Holdings Inc

ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.

The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Nvidia Corp

NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.

Read more on NVDA

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH